Resultados de la búsqueda 51-60 of 8283 for 斑马ai网址,绘画 ai 网站,ai聊天网页版入口,批改网ai写作,用ai做网页设计,等欢迎访问豌豆Ai站群搜索引擎系统官方网站:www.wd.chat
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...
The four cancer types are: Non-Small Cell Lung Cancer (NSCLC) and melanoma that are progressing on checkpoint inhibitor (CPI, generally refers to anti-PD(L)1 ...
Evaluation of the Total Kidney Volume AI Algorithm. Rochester, Minn. The natural course of autosomal dominant polycystic kidney disease (ADPKD) is highly ...
Centralized follow-up will be conducted by having sites upload patient data following each visit via the web-based data system, with patients who do not ...
The objectives of this study are: To evaluate patient-reported quality of life and functional vision across the spectrum of pediatric eye conditions; ...
Rochester, Minn., Scottsdale/Phoenix, Ariz. This is a peripheral blood Collection Protocol to study the T-cell immune responses of patients with malignancies ...
The aim of this study is to create a patient and patient-advocate catalyzed tumor bank for the retrieval, processing, analysis, and maintenance of ...
All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with CD22 positive B acute lymphoblastic leukemia that has come ...
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with CD22 positive B acute lymphoblastic leukemia that has ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?